

Author: Blackberg M. Ohlsson K.
Publisher: Informa Healthcare
ISSN: 0036-5513
Source: Scandinavian Journal of Clinical and Laboratory Investigation, Vol.61, Iss.1, 2001-02, pp. : 57-67
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Tissue kallikrein is released in the body both physiologically and in many inflammatory disorders. Little is, however, known about the turnover of released tissue kallikrein in humans. Approximately 1 mg of tissue kallikrein (mol wt 43 000 Da) was purified from 85 L human urine by: (1) ultracentrifugation, (2) filtration through an aprotinin-coupled Sepharose 4B column, followed by (3) gel filtration over a Sephadex G-75 column. The elimination, after intraduodenal or intravenous administration of purified tissue kallikrein radiolabelled with 125I, was followed by collecting serial samples of plasma, urine and faeces from three volunteers. Within 72 h, about 96% of the intraduodenally administered radioactivity had been excreted in urine, and approximately 5.4% in faeces, mainly as 125I. No intact 125I-tissue kallikrein was found in plasma, urine or faeces after the intraduodenal instillation of the protein. The plasma half-life of 125I-tissue kallikrein up to 3 h after intravenous injection was 9 min and, thereafter, 20 h. The 125I-tissue kallikrein was quickly bound to a plasma protein with a mol wt of about 67 kDa, but some of the radioiodinated tissue kallikrein was still unbound 15 min after injection, judged by gel filtration on Sephadex G-200 columns. Most of the radioactivity was excreted in the urine as 125I, but about 4- 6% was recovered as free 125I-tissue kallikrein.
Related content




By Lankveld Daniëëlle PK Rayavarapu Raja G Krystek Petra Oomen Agnes G Verharen Hennie W van Leeuwen Ton G De Jong Wim H Manohar Srirang
Nanomedicine, Vol. 6, Iss. 2, 2011-02 ,pp. :



